Les Meilleurs doctors pour le traitement de leucémie lymphoblastique aiguë en Israël - TOP-20 des médecins

Le Dr Ram Ron exerce au sein de l'un des plus grands et des principaux hôpitaux d'enseignement publics d'Israël, le Sourasky Medical Center (Ichilov), reconnu pour la qualité de ses soins et son innovation médicale.

• Accéder à des traitements et technologies de pointe dans un hôpital universitaire de premier plan
• Faire partie d'une équipe d'hémato-oncologie multidisciplinaire et complète
• Bénéficier d'un centre dédié à la fois aux soins des patients et à la recherche
• Travailler dans un hôpital accrédité par la Joint Commission International

Le Dr Ron Ram a réalisé plusieurs centaines de greffes de cellules souches, une procédure clé pour la leucémie lymphoblastique aiguë, en tant qu'hématologue-oncologue certifié.

• Certification en hématologie et en oncologie médicale
• Formation lors d'un clinicat (fellowship) en hématologie et oncologie au New York Medical College
• Publication de plus de 30 articles scientifiques sur les affections hématologiques
• Auteur d'un chapitre dans un manuel médical

Le Dr Ronit El Hasid a réalisé plus de 300 transplantations de moelle osseuse et de sang de cordon ombilical pour des enfants à l'hôpital pour enfants Dana Dwek.

• Chef du département d'onco-hématologie et d'oncologie pédiatrique
• Plus de 50 publications et plus de 40 rapports de conférence
• Membre de l'Association américaine d'hématologie
• Formée au City of Hope Hospital de Los Angeles

Prof. Amos Toren, MD, PhD, MHA, is a pediatric hemato-oncologist and BMT specialist. He served as Director of Pediatric Hemato-Oncology and BMT at Sheba Medical Center.

He is board certified in Pediatrics, Pediatric Hemato-Oncology, and Bone Marrow Transplantation. He holds a PhD in Human Genetics. He was Head of the Hematology Division at Tel Aviv University for two terms. He is a member of ASH, COG, ESPHI, EBMT, and CIBMTR. He also serves on the Ministry of Health Cord Blood Committee.

He led one of Israel’s most advanced pediatric oncology and BMT programs. The program treated children and young adults. His focus includes leukemia and lymphoma, immunodeficiencies, and rare cancers. He specializes in BMT and CAR T-cell therapy.

His translational research covers CAR T cells, cytokine-induced killer cells, pediatric brain tumors, and targeted therapies. He has worked with St. Anna, the NIH, and St. Jude. His publications include studies on pediatric SCT prophylaxis and PARP resistance.

Dr. Hana Golan, MD, heads the Pediatric Hemato-Oncology and Bone Marrow Transplantation (BMT) Division at Sheba Medical Center. She specializes in childhood cancers, with a focus on neuroblastoma and other high-risk solid tumors.

She leads one of the region’s most advanced pediatric oncology programs. She manages complex, high-risk cases and practices at a hospital ranked in the global top 10.

She is the principal investigator of the High-Risk Neuroblastoma ESIOP protocol. She serves as an investigator in international Phase I/II trials and as the national coordinator of multicenter oncology protocols. She led the development of computerized chemotherapy protocols and patient databases to improve safety.

She earned her MD from the Technion. She completed residencies in pediatrics and pediatric hemato-oncology at Sheba. She conducted advanced research in transplantation immunology at the Weizmann Institute. She is board-certified in Pediatrics and Pediatric Hematology-Oncology. She is a Senior Lecturer at the Sackler Faculty of Medicine, Tel Aviv University. Her research focuses on cancer stem cells, targeted therapies, treatment-resistant malignancies, and cannabinoid-related oncology.

Le Dr Michael Shapira se spécialise exclusivement dans la greffe de moelle osseuse au centre médical Sourasky, un leader des traitements hématologiques.

• Diplômé de la faculté de médecine de l'Université hébraïque en 1999
• Spécialisé en médecine interne au centre médical Hadassah
• Médecin principal en transplantation de moelle osseuse à Hadassah
• Maîtrise de l'anglais et de l'hébreu

Le Dr Dror Levin dirige le département d'hématologie et d'oncologie pédiatrique au centre médical Sourasky de Tel Aviv, l'un des meilleurs hôpitaux d'Israël.

• Expert principal dans le traitement des troubles sanguins et des cancers des os chez l'enfant
• Formé en oncologie pédiatrique au centre médical pour enfants Schneider
• Spécialisé en hématologie pédiatrique, y compris les troubles de la coagulation chez les prématurés
• A étudié le traitement des sarcomes à l'Institut orthopédique Rizzoli de renommée mondiale
• Membre actif de la Société israélienne d'hémato-oncologie pédiatrique

Le Dr Fredi Aviv apporte plus de 31 ans de pratique ciblée en tant qu'onco-hématologue au centre médical de pointe Sourasky de Tel-Aviv.

• Se spécialiser exclusivement dans les cancers du sang tels que la leucémie et le lymphome
• Justifier d'un long parcours dans un centre hospitalier universitaire et de recherche majeur
• Offrir une expérience approfondie tant en matière de diagnostics initiaux que de plans de traitements complexes
• Permettre l'accès aux dernières thérapies hospitalières et aux essais cliniques

Le Dr Herishanu a reçu plusieurs prix prestigieux pour ses recherches sur la leucémie lymphoïde chronique.

• Plus de 30 ans d'expérience médicale en tant qu'hématologue
• Auteur de nombreux articles de recherche publiés
• Formé en hématologie au centre médical de Tel Aviv
• Membre des associations américaine et israélienne d'hématologie

Dr. Abraham Avigdor, MD, is Director of the Institute of Hematology and Co‑Director of the Hematology & Bone Marrow Transplantation Division at Sheba Medical Center. He is an international leader in lymphoma, CAR‑T, and advanced hemato‑oncology with more than 35 years of experience. His clinical focus includes lymphomas, multiple myeloma, and complex blood cancers.

He is a pioneer in CAR‑T integration. He leads cellular therapy and bone marrow transplantation programs (autologous and allogeneic). He also advances stem cell therapies and precision diagnostics, including PET/CT‑based prognostics. His work includes immunotherapy and targeted regimens and the development of innovative, data‑driven protocols.

He collaborates with LYSA, EMCL, and international PET groups. He has authored more than 130 publications. Key roles include Founder and President of the Israeli Lymphoma Working Group, former Chair of the Israeli Lymphoma Study Group, and Senior Lecturer at Tel Aviv University. Education: MD, Ben‑Gurion University; residency, Sheba Medical Center; postdoctoral fellowship, Weizmann Institute. Awards include the Knesset Prize, the Israeli Ministry of Health Award, and the Sackler Prize.

Prof. Avichai Shimoni, MD, is Director of Bone Marrow Transplantation at Sheba Medical Center. He is a hemato-oncologist with over 30 years of experience in bone marrow transplantation, cellular therapies, and advanced blood cancer care.

He leads a high-volume program for complex, high-risk blood cancers. He performs allogeneic and autologous transplants. He also provides CAR T-cell therapy for leukemia, lymphoma, and multiple myeloma. He completed a bone marrow transplantation fellowship at MD Anderson Cancer Center.

He is Chairman of Hematology at Tel Aviv University and a Professor of Hematology. He has authored more than 250 scientific papers. His research focuses on CAR T-cell therapy and stem cell transplantation. He is often listed among Israel's Best Doctors (Forbes 2025 and 2026).

Dr. Hila Magen, MD, leads the Multiple Myeloma and Amyloidosis Unit at Sheba Medical Center. She is a hemato-oncologist with over 35 years of experience. She is a leading Israeli expert in multiple myeloma and plasma cell disorders.

She runs a program that provides personalized care and early access to clinical trials. This includes CAR-T therapy for high-risk and relapsed or refractory myeloma and amyloidosis. Dr. Magen is a principal investigator in point-of-care CAR-T studies. She brings new immunotherapies into routine care.

Training: Fellowships in Multiple Myeloma (UAMS) and Lymphocytic Leukemia (MD Anderson). Academic: Instructor, Tel Aviv University. Research: Author of 100+ publications, contributor to landmark myeloma studies, and reviewer for international journals.

Dr. Iris Kventsel, MD, is a pediatric hemato-oncologist and bone marrow transplant (BMT) specialist at Sheba Medical Center. She is an attending physician in the Pediatric Hemato-Oncology and BMT Division at the Edmond and Lily Safra Children’s Hospital. Her clinical focus is pediatric sarcomas, including Ewing sarcoma, osteosarcoma, and rhabdomyosarcoma.

She provides multidisciplinary care, including transplant and cellular therapies. She also uses current chemotherapy protocols and targeted therapies for complex childhood cancers.

Her research focuses on genetic cancer predisposition, including Li-Fraumeni syndrome, and cancer susceptibility genes. She has published in pediatric oncology, stem cell biology, and surgical oncology (HIPEC). She is on the academic staff at Tel Aviv University. Education: MD, Technion; Pediatrics residency, Assaf HaRofeh; Pediatric Hemato-Oncology fellowship, Sheba.

Prof. Elad Jacoby, MD, heads the Pediatric Cell Therapy Center at Sheba Medical Center. He is the Medical Director of the Advanced Biotherapy Center. He is a pioneer of pediatric CAR T‑cell therapy in Israel. He led one of the first national leukemia programs. He has almost 20 years of clinical and research experience.

He specializes in CAR T‑cell therapy, bone marrow and stem cell transplantation, and high‑risk pediatric leukemias and lymphomas. He leads international clinical trials and has authored over 240 publications. His collaborations include Johns Hopkins Hospital and the U.S. National Cancer Institute. He is an Associate Professor at Tel Aviv University. He received his MD from Tel Aviv University, completed residency at Sheba Medical Center, and fellowships at Johns Hopkins and the National Cancer Institute. He is board‑certified in Pediatrics and in Pediatric Hematology and Oncology. He serves on the IBFM CAR T‑Cell Taskforce and the Sheba Institutional Review Board. He leads the integration of CAR T‑cell therapy with transplantation.

Le professeur Zila Zuckerman est spécialisée en hématologie et en transplantologie au centre médical Rambam.

• Experte dans le traitement de la leucémie lymphoblastique aiguë
• Spécialisée en transplantologie pour les troubles sanguins
• Professeur ayant une vaste expérience académique et clinique

Chef du service d'hématologie au centre médical Hadassah – Le professeur Ben-Yehuda a été pionnier dans la thérapie génique et les greffes de moelle osseuse pour la leucémie aiguë lymphoblastique.

• Formée au Memorial Sloan-Kettering Cancer Center à New York
• Première femme doyenne de la faculté de médecine Hadassah
• Spécialisée en diagnostic moléculaire et en immunologie
• Lauréate du prix Healing with the Heart pour l'excellence des soins aux patients

Reconnu par Forbes comme l'un des meilleurs médecins en 2018 – le Dr Stepensky a réalisé plus de 3 500 greffes de moelle osseuse au centre médical Hadassah.

• 20 ans de spécialisation dans les greffes de moelle osseuse pédiatriques
• Concentration sur les maladies rares du cancer du sang chez les enfants
• Connu par les patients comme « celui qui transplante la vie »
• Diriger une unité d'hématologie pédiatrique dédiée

Le Dr Ofer Spielberg est un onco-hématologue spécialisé, se concentrant sur les cancers du sang tels que la leucémie.

• Exercer au centre médical Assuta
• Expertise en onco-hématologie, le domaine dédié aux cancers du sang
• Proposer des traitements ciblés pour la leucémie lymphoblastique aiguë